Study #2023-0858
18F-ARAG PET/CT as a non-invasive imaging biomarker for chemoradiation treatment response in esophageal cancer
MD Anderson Study Status
Enrolling
Treatment Agent
ArabinoFuranosylGuanine [18F]F-AraG
Description
To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Esophageal Cancer
Study phase:
Phase I (Early)
Physician name:
Steven Lin
Department:
Radiation Oncology
For general questions about clinical trials:
1-855-807-9574
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.